ReVeRA-301
Multi-Center, Multi-National, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR)
- Stage
- inclusie
- Medicine
- Etripamil
- Population
- Ritme
- Phase
- III
- First Patient In
- 1 September 2026
- Last Patient In
- 1 September 2028
- Last Patient Last Visit
- -
Inclusion period, 700 days remaining
Study Director
dr. A.M.W. Alings
Cardioloog
Office Contact
